๐ EyePoint Pharma $EYPT craters -70% premarket โ wet AMD Phase 3 LUGANO trial misses endpoint
EyePoint Pharmaceuticals (EYPT) is in freefall this morning after its DURAVYU drug failed the primary endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. The treatment could not show non-inferiority in preserving best-corrected vision across the full trial population, a devastating blow to the lead pipeline. Stock is tracking 16-month lows with no clear path forward for Duravyu. Is EYPT now a buyout candidate or a broken story? Not financial advice.
โก 17 buzzing
360 views
๐ 0 subscribed